• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Rexahn Pharmaceuticals Reports Full Year 2017 Financial Results

    Gabrielle Lakusta
    Mar. 12, 2018 08:41AM PST
    Pharmaceutical Investing

    Rexahn Pharmaceuticals (NYSE:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced financial results for the year ended December 31, 2017. As quoted in the press release: “We continue to make significant progress in the development of our product candidates,” said Peter D. Suzdak, Ph.D., chief executive officer …

    Rexahn Pharmaceuticals (NYSE:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, today announced financial results for the year ended December 31, 2017.

    As quoted in the press release:

    “We continue to make significant progress in the development of our product candidates,” said Peter D. Suzdak, Ph.D., chief executive officer of Rexahn. “In 2017, we advanced RX-5902 into a Phase 2a trial in triple negative breast cancer and initiated a Phase 2a trial of RX-3117 in patients newly diagnosed with metastatic pancreatic cancer. Importantly, data presented last year demonstrated that RX-5902 enhanced the efficacy of immunotherapy agents in multiple preclinical models. In addition, we recently extended the intellectual property position on RX-3117 and RX-5902 and strengthened our leadership team. We also announced a collaboration to advance RX-0201 using non-dilutive capital through a proof of concept trial in hepatocellular carcinoma.”

    Click here to read the full press release.

    pharmaceutical investingmetastatic pancreatic cancerbreast cancerclinical-stage biopharmaceuticalfinancial resultsleadership teamclinical-stage biopharmaceutical companypancreatic cancer
    The Conversation (0)

    Go Deeper

    AI Powered
    Pharma Outlook

    Pharma Outlook

    Radiopharm Theranostics

    Radiopharm Theranostics

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

     
    IVX:AU

    Cardiol Therapeutics

     
    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×